Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[MALT lymphoma].

T Kageyama1, T Yagi, M Hasegawa

  • 12nd Department of Internal Medicine, Osaka Medical College.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 31, 2000
PubMed
Summary
This summary is machine-generated.

Mucosa-associated lymphoid tissue (MALT) lymphoma, an extranodal lymphoma, is an established disease entity. This review covers its concept, pathology, diagnosis, therapy, and future research directions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circadian rhythms of pineal melatonin release in the pigeon measured by in vivo microdialysis.

Neuroscience letters·1992
Same author

[A new steroid therapy for difficult asthmatics--an induction and maintenance, two-step therapy].

Arerugi = [Allergy]·1992
Same author

[Analgesic effects of epidurally administered fentanyl for postoperative pain relief--comparison with buprenorphine].

Masui. The Japanese journal of anesthesiology·1992
Same author

Organization and nature of fortimicin A (astromicin) biosynthetic genes studied using a cosmid library of Micromonospora olivasterospora DNA.

Molecular & general genetics : MGG·1992
Same author

N-formimidoyl fortimicin A synthase, a unique oxidase involved in fortimicin A biosynthesis: purification, characterization and gene cloning.

Molecular & general genetics : MGG·1992
Same author

Improvement in the heterogeneous N-termini and the defective N-glycosylation of human interleukin-6 by genetic engineering.

European journal of biochemistry·1992
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • MALT lymphoma, first described in 1983, originates in the extranodal marginal zone of mucosa-associated lymphoid tissue.
  • It was incorporated into the Revised European-American Lymphoma (REAL) classification in 1994, establishing it as a distinct disease entity.
  • Recent research has intensified interest in this specific type of lymphoma.

Purpose of the Study:

  • To provide a comprehensive overview of MALT lymphoma.
  • To discuss the current understanding of its disease concept, pathology, diagnosis, and therapeutic strategies.
  • To survey relevant literature and outline future research and management outlook.

Main Methods:

  • Literature review of MALT lymphoma.
  • Analysis of disease concept, pathology, diagnosis, and therapy.

Related Experiment Videos

  • Survey of current research and management trends.

    • Main Results:

    • MALT lymphoma is a recognized extranodal lymphoma entity.
    • Established diagnostic criteria and therapeutic approaches exist.
    • Ongoing research continues to refine understanding and management.

    Conclusions:

    • MALT lymphoma is a well-defined clinicopathological entity.
    • Comprehensive understanding of its characteristics aids in diagnosis and treatment.
    • Continued research is crucial for advancing patient outcomes.